ArgusEye Secures €2.8 Million to Revolutionize Bioprocessing
May 15, 2024, 7:35 am
Description at least 700 words
ArgusEye, a Swedish innovator in sensor solutions for biological systems, has just closed a significant funding round of €2.8 million. This injection of capital, led by Voima Ventures and co-led by Eir Ventures, marks a pivotal moment in the company's journey towards transforming the bioprocessing landscape.
Founded in 2017 by Erik Martinsson and Daniel Aili, ArgusEye has been on a mission to revolutionize the way biological systems are monitored and analyzed in real-time. Their cutting-edge sensor technology, based on localized surface plasmon resonance (LSPR) using gold nanoparticles, has the potential to streamline and accelerate the development and manufacture of biotherapeutics.
The recent introduction of the AugaOne™ product, the first in ArgusEye's Auga sensor system platform, has already shown promise in downstream processing by enhancing process efficiency and facilitating the detection and quantification of monoclonal antibodies (mAbs). With this new funding, ArgusEye aims to expand the Auga platform to cover upstream bioprocessing and formulation, catering to a wider range of target molecules and significantly impacting the biotherapeutic development and production process.
Jenny Engerfelt, Investment Director at Voima Ventures, expressed optimism about ArgusEye's technology, highlighting its potential to reduce healthcare costs and improve health outcomes by optimizing biopharmaceutical manufacturing processes. This sentiment was echoed by Lene Gerlach, Partner at Eir Ventures, who emphasized the company's commitment to bringing revolutionary sensor technologies to life and making medicines more accessible to a larger population while reducing the ecological footprint.
As ArgusEye enters its scale-up phase, CEO Erik Martinsson outlined the company's strategic priorities, which include expanding their market presence globally and diversifying their product offerings to cover the entire pharmaceutical process chain. By focusing on delivering cutting-edge solutions that address the evolving needs of the biopharmaceutical industry, ArgusEye aims to democratize access to biomedicines and promote sustainability in biopharma manufacturing through real-time quality control.
In conclusion, ArgusEye's recent funding success is a testament to the potential of their innovative sensor technology to revolutionize bioprocessing. With a clear vision and a commitment to driving positive change in the industry, ArgusEye is poised to make a significant impact on the future of biotherapeutic development and production. Visit their website to learn more about the Auga platform and the exciting advancements in real-time monitoring of biological systems.
ArgusEye, a Swedish innovator in sensor solutions for biological systems, has just closed a significant funding round of €2.8 million. This injection of capital, led by Voima Ventures and co-led by Eir Ventures, marks a pivotal moment in the company's journey towards transforming the bioprocessing landscape.
Founded in 2017 by Erik Martinsson and Daniel Aili, ArgusEye has been on a mission to revolutionize the way biological systems are monitored and analyzed in real-time. Their cutting-edge sensor technology, based on localized surface plasmon resonance (LSPR) using gold nanoparticles, has the potential to streamline and accelerate the development and manufacture of biotherapeutics.
The recent introduction of the AugaOne™ product, the first in ArgusEye's Auga sensor system platform, has already shown promise in downstream processing by enhancing process efficiency and facilitating the detection and quantification of monoclonal antibodies (mAbs). With this new funding, ArgusEye aims to expand the Auga platform to cover upstream bioprocessing and formulation, catering to a wider range of target molecules and significantly impacting the biotherapeutic development and production process.
Jenny Engerfelt, Investment Director at Voima Ventures, expressed optimism about ArgusEye's technology, highlighting its potential to reduce healthcare costs and improve health outcomes by optimizing biopharmaceutical manufacturing processes. This sentiment was echoed by Lene Gerlach, Partner at Eir Ventures, who emphasized the company's commitment to bringing revolutionary sensor technologies to life and making medicines more accessible to a larger population while reducing the ecological footprint.
As ArgusEye enters its scale-up phase, CEO Erik Martinsson outlined the company's strategic priorities, which include expanding their market presence globally and diversifying their product offerings to cover the entire pharmaceutical process chain. By focusing on delivering cutting-edge solutions that address the evolving needs of the biopharmaceutical industry, ArgusEye aims to democratize access to biomedicines and promote sustainability in biopharma manufacturing through real-time quality control.
In conclusion, ArgusEye's recent funding success is a testament to the potential of their innovative sensor technology to revolutionize bioprocessing. With a clear vision and a commitment to driving positive change in the industry, ArgusEye is poised to make a significant impact on the future of biotherapeutic development and production. Visit their website to learn more about the Auga platform and the exciting advancements in real-time monitoring of biological systems.